butyl 7-[(2R)-2-(hydroxymethyl)-5-thioxo-1-pyrrolidinyl]heptanoate | 729612-09-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: butyl 7-[(2R)-2-(hydroxymethyl)-5-thioxo-1-pyrrolidinyl]heptanoate
• 英文别名: butyl 7-[(2R)-2-(hydroxymethyl)-5-sulfanylidenepyrrolidin-1-yl]heptanoate
• CAS: 729612-09-3
• 化学式: C₁₆H₂₉NO₃S
• 分子量: 315.477
• InChiKey: RLWKCCVPNURNTR-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  81.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  butyl 7-[(2R)-2-(hydroxymethyl)-5-thioxo-1-pyrrolidinyl]heptanoate 在 硼烷四氢呋喃络合物 、 三氧化硫吡啶 、 sodium hydride 、 二甲基亚砜 、 N,N-二异丙基乙胺 、 sodium hydroxide 、 (R)-2-甲基-CBS-恶唑硼烷 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 乙酸乙酯 、 甲苯 、 mineral oil 为溶剂， 反应 19.41h， 生成 7-{(2R)-2-[(1E,3S)-4-(3-ethylphenyl)-3-hydroxybut-1-enyl]-5-thioxopyrrolidin-1-yl}heptanoic acid
  参考文献：
  名称：

  Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists

  摘要：

  To identify chemically and metabolically stable subtype-selective EP4 agonists, design and synthesis of a series of modified gamma-lactam prostanoids has been continued. Prostanoids bearing 2-oxo-1,3-oxazolidine, 2-oxo-1,3-thiazolidine and 5-thioxopyrrolidine as a surrogate for the gamma-hydroxycyclopentanone without a troublesome 11-hydroxy group were identified as highly subtype-selective EP4 agonists. Among the tested, several representative compounds demonstrated in vivo efficacy after oral dosing in rats. Their pharmacokinetic and structure-activity relationship studies are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.009
• 作为产物：
  描述：

  在 劳森试剂 、 咪唑 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 3.5h， 生成 butyl 7-[(2R)-2-(hydroxymethyl)-5-thioxo-1-pyrrolidinyl]heptanoate
  参考文献：
  名称：

  Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists

  摘要：

  To identify chemically and metabolically stable subtype-selective EP4 agonists, design and synthesis of a series of modified gamma-lactam prostanoids has been continued. Prostanoids bearing 2-oxo-1,3-oxazolidine, 2-oxo-1,3-thiazolidine and 5-thioxopyrrolidine as a surrogate for the gamma-hydroxycyclopentanone without a troublesome 11-hydroxy group were identified as highly subtype-selective EP4 agonists. Among the tested, several representative compounds demonstrated in vivo efficacy after oral dosing in rats. Their pharmacokinetic and structure-activity relationship studies are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.009

文献信息

• 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICAL USE THEREOF
  申请人：Kambe Tohru

  公开号：US20080033033A1

  公开（公告）日：2008-02-07

  The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP 4 agonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and/or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

  本发明的化合物具有8-氮杂前列腺素骨架，其化学式为(I)，其中所有符号的含义与规范相同。该药物组合物包括该化合物、其盐、溶剂化物或环糊精包合物，或其前药，作为活性成分具有EP4激动作用，因此被认为对预防和/或治疗免疫性疾病、哮喘、神经细胞死亡、关节炎、肺功能衰竭、肺纤维化、肺气肿、支气管炎、慢性阻塞性肺疾病、肝损伤、急性肝炎、肾炎、肾功能不全、高血压、心肌缺血、全身炎症反应综合征、败血症、血液嗜酸细胞综合征、巨噬细胞激活综合征、斯蒂尔氏病、川崎病、烧伤、全身性肉芽肿病、溃疡性结肠炎、克隆氏病、透析时的高细胞因子血症、多器官衰竭、休克和青光眼等具有用处。此外，这些化合物还具有加速骨形成的作用，因此有望用于预防和/或治疗与骨量减少有关的疾病，例如原发性骨质疏松症、继发性骨质疏松症、骨转移性癌症、高钙血症、帕吉特病、骨质流失、骨坏死、骨手术后的骨形成、骨移植的替代治疗。
• 8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICINAL USES THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1586564B1

  公开（公告）日：2012-11-28
• US7256211B1
  申请人：——

  公开号：US7256211B1

  公开（公告）日：2007-08-14
• Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists
  作者：Tohru Kambe、Toru Maruyama、Toshihiko Nagase、Seiji Ogawa、Chiaki Minamoto、Kiyoto Sakata、Takayuki Maruyama、Hisao Nakai、Masaaki Toda

  DOI：10.1016/j.bmc.2011.12.009

  日期：2012.1

  To identify chemically and metabolically stable subtype-selective EP4 agonists, design and synthesis of a series of modified gamma-lactam prostanoids has been continued. Prostanoids bearing 2-oxo-1,3-oxazolidine, 2-oxo-1,3-thiazolidine and 5-thioxopyrrolidine as a surrogate for the gamma-hydroxycyclopentanone without a troublesome 11-hydroxy group were identified as highly subtype-selective EP4 agonists. Among the tested, several representative compounds demonstrated in vivo efficacy after oral dosing in rats. Their pharmacokinetic and structure-activity relationship studies are presented. (C) 2011 Elsevier Ltd. All rights reserved.